ex vivo HBB-transduced autologous hematopoietic stem cell therapy (Allife Medical Science and Technology)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameex vivo HBB-transduced autologous hematopoietic stem cell therapy (Allife Medical Science and Technology)

Drug Alias NameHBB gene-tranduced iHSCs (Allife Medical Science and Technology)ex vivo CRISPR/Cas9/HBB stem cell-based gene therapy (Allife Medical Science and Technology)Ex Vivo HBB-Edited Hematopoietic Stem Cell Therapy (Allife Medical Science and Technology)ex vivo HBB-transduced autologous hematopoietic stem cell therapy (Beijing Allife Medicine Technology)

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionHemoglobin beta chain stimulants

TargetsHemoglobin beta chain

Therapy Area/Indicationsbeta-Thalassemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesEpsilon Molecular Engineering Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEpsilon Molecular Engineering Inc

Active IndicationsN/A

Inactive Indicationsbeta-Thalassemia

Other Information

ATC CodeN/A